Retatrutide 30MG

Product overview

Retatrutide 30MG is a peptide research material supplied in a 30mg vial presentation (SKU RT30). It is a separate catalogue amount of the same named molecule listed in the 10mg and 20mg presentations.

Retatrutide, also called LY3437943, is studied for its activity at three receptor systems: GLP-1, GIP and glucagon. These receptors help cells respond to metabolic signals.

What researchers study

• How GLP-1, GIP and glucagon receptors respond in controlled tests
• Receptor selectivity and the signals produced inside cells
• Metabolic responses in defined laboratory models
• Analytical identity, peptide content and batch-to-batch consistency

Evidence and limitations

Research includes receptor experiments, preclinical models and clinical development of sponsor-made investigational formulations. Findings from those materials do not establish the identity, purity or performance of this independently supplied vial.

The molecular identifiers describe the reference molecule. The supplied salt form, formulation and batch results must be checked against the relevant documentation. A larger catalogue amount does not establish a different mechanism or research outcome.

Regulatory context

At the review date, retatrutide remains investigational and has not been authorised for use in the UK. This ExtolX listing is for laboratory research material; it is not an authorised medicine or sponsor-supplied clinical-trial product.

Storage and laboratory handling

Before preparing a solution: Keep the original vial closed and follow the product label, safety data and batch documentation for storage conditions. Storage information for a reference material does not establish a shelf life for this ExtolX batch.

After preparing a solution: No batch-specific solution stability or universal compatibility has been verified. The laboratory must validate the solvent, concentration, container, temperature and hold time for its method.

Handle only in an appropriately equipped laboratory using suitable personal protective equipment and local disposal procedures.

Sources

• MedChemExpress: retatrutide reference identity and technical information
• Lilly: current retatrutide development information
• MHRA: UK authorisation status of retatrutide

Scientific sources last reviewed: 26 October 2026.

Research use

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.